Tudor Investment Corp ET AL Makes New $2.03 Million Investment in Mirum Pharmaceuticals, Inc. $MIRM

Tudor Investment Corp ET AL acquired a new stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 27,654 shares of the company’s stock, valued at approximately $2,027,000. Tudor Investment Corp ET AL owned about 0.05% of Mirum Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of MIRM. CIBC Bancorp USA Inc. acquired a new position in shares of Mirum Pharmaceuticals in the 3rd quarter worth $315,000. PharVision Advisers LLC purchased a new stake in shares of Mirum Pharmaceuticals during the third quarter valued at $273,000. Virtus Advisers LLC purchased a new stake in shares of Mirum Pharmaceuticals during the third quarter valued at $293,000. Voleon Capital Management LP acquired a new position in shares of Mirum Pharmaceuticals in the 3rd quarter valued at $6,343,000. Finally, Voloridge Investment Management LLC boosted its position in shares of Mirum Pharmaceuticals by 2,116.6% in the 3rd quarter. Voloridge Investment Management LLC now owns 389,574 shares of the company’s stock valued at $28,560,000 after purchasing an additional 371,999 shares during the period.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Cantor Fitzgerald restated an “overweight” rating and set a $130.00 price objective on shares of Mirum Pharmaceuticals in a report on Monday, December 8th. Royal Bank Of Canada decreased their target price on shares of Mirum Pharmaceuticals from $130.00 to $128.00 and set an “outperform” rating for the company in a report on Thursday, February 26th. Morgan Stanley lifted their target price on shares of Mirum Pharmaceuticals from $95.00 to $123.00 and gave the stock an “overweight” rating in a research report on Friday, January 30th. Citizens Jmp cut their price target on shares of Mirum Pharmaceuticals from $140.00 to $132.00 and set a “market outperform” rating on the stock in a report on Thursday, February 26th. Finally, Wall Street Zen downgraded shares of Mirum Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Saturday, February 28th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $117.67.

Mirum Pharmaceuticals Stock Performance

Shares of MIRM opened at $88.44 on Friday. The company has a market capitalization of $5.34 billion, a PE ratio of -184.25 and a beta of 0.52. The company has a debt-to-equity ratio of 0.98, a quick ratio of 2.55 and a current ratio of 2.67. The company’s 50 day moving average price is $96.36 and its 200 day moving average price is $81.75. Mirum Pharmaceuticals, Inc. has a 52 week low of $36.88 and a 52 week high of $109.28.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its earnings results on Wednesday, February 25th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.13). The company had revenue of $148.93 million during the quarter, compared to analysts’ expectations of $141.78 million. Mirum Pharmaceuticals had a negative return on equity of 8.53% and a negative net margin of 4.48%.The firm’s quarterly revenue was up 49.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.00 EPS. Research analysts expect that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current fiscal year.

Insider Buying and Selling at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 4,732 shares of the business’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $91.98, for a total value of $435,249.36. Following the transaction, the senior vice president owned 8,429 shares in the company, valued at $775,299.42. The trade was a 35.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Joanne Quan sold 7,287 shares of the company’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $91.98, for a total value of $670,258.26. Following the completion of the transaction, the insider directly owned 18,864 shares in the company, valued at approximately $1,735,110.72. The trade was a 27.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 121,942 shares of company stock valued at $11,416,645 in the last quarter. Corporate insiders own 14.36% of the company’s stock.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.